Pfizer Announces Publication of New Analysis Showing Long-Term Therapy with Vyndaqel (tafamidis) Slowed Progression of Rare Neurodegenerative Disease

August 8, 2016 - Pfizer Inc. (NYSE:PFE) announced the publication of a new post-hoc analysis of data from three studies of Vyndaqel in patients with mild transthyretin familial amyloid polyneuropathy (TTR-FAP). The analysis, which included patients...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news